share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Roberts M Scot

SEC announcement ·  Feb 6 07:04
Summary by Futu AI
Altimmune, Inc.'s Chief Scientific Officer, M Scot Roberts, completed a series of transactions involving the company's common stock on February 1 and 2, 2024. Roberts acquired a total of 13,941 shares through the exercise of derivative securities at no cost. Concurrently, Roberts disposed of 4,131 shares to cover exercise prices or tax liabilities, with the transactions priced between $9.32 and $9.88 per share, resulting in a total market value of $39,509.48. Following these transactions, Roberts directly holds 42,660 shares of Altimmune. Additionally, an indirect holding of 15 shares is reported, owned by the spouse of the reporting person.
Altimmune, Inc.'s Chief Scientific Officer, M Scot Roberts, completed a series of transactions involving the company's common stock on February 1 and 2, 2024. Roberts acquired a total of 13,941 shares through the exercise of derivative securities at no cost. Concurrently, Roberts disposed of 4,131 shares to cover exercise prices or tax liabilities, with the transactions priced between $9.32 and $9.88 per share, resulting in a total market value of $39,509.48. Following these transactions, Roberts directly holds 42,660 shares of Altimmune. Additionally, an indirect holding of 15 shares is reported, owned by the spouse of the reporting person.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.